CN108948211B - 一种基于靶向gd2的嵌合抗原受体及其应用 - Google Patents
一种基于靶向gd2的嵌合抗原受体及其应用 Download PDFInfo
- Publication number
- CN108948211B CN108948211B CN201810821559.9A CN201810821559A CN108948211B CN 108948211 B CN108948211 B CN 108948211B CN 201810821559 A CN201810821559 A CN 201810821559A CN 108948211 B CN108948211 B CN 108948211B
- Authority
- CN
- China
- Prior art keywords
- chimeric antigen
- antigen receptor
- domain
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 74
- 230000008685 targeting Effects 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 48
- 239000000427 antigen Substances 0.000 claims abstract description 34
- 108091007433 antigens Proteins 0.000 claims abstract description 34
- 102000036639 antigens Human genes 0.000 claims abstract description 34
- 230000011664 signaling Effects 0.000 claims abstract description 29
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 13
- 102000004039 Caspase-9 Human genes 0.000 claims abstract description 9
- 108090000566 Caspase-9 Proteins 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 25
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 25
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 239000013603 viral vector Substances 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 11
- 241000713666 Lentivirus Species 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000000139 costimulatory effect Effects 0.000 abstract description 5
- 230000004083 survival effect Effects 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 230000004068 intracellular signaling Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 229940088592 immunologic factor Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010027076 Mediastinal mass Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22062—Caspase-9 (3.4.22.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Abstract
本发明涉及一种基于靶向GD2的嵌合抗原受体,所述嵌合抗原受体包括抗原结合结构域、跨膜结构域、共刺激信号传导结构域、CD3ζ信号传导结构域和自毁结构域串联而成;其中,所述抗原结合结构域结合肿瘤表面抗原,所述肿瘤表面抗原为GD2,所述抗原结合结构域为针对肿瘤表面抗原GD2的单链抗体,所述自毁结构域为胱天蛋白酶9结构域。本发明的嵌合抗原受体实际应用于表达肿瘤特异靶点GD2的IV期神经母细胞瘤病人中,有更小的临床副作用与更高的安全性,可有效缩小实体瘤灶,并于病人体内长期监测到GD2‑CART的存在,有效延长病人整体生存率。
Description
技术领域
本发明涉及肿瘤的细胞免疫治疗领域,尤其涉及一种基于靶向GD2的嵌合抗原受体及其应用,具体为以肿瘤特异靶点GD2为基础的嵌合抗原受体T(CAR-T)细胞技术的构建方法及其在抗肿瘤治疗中的应用。
背景技术
随着肿瘤免疫学理论和临床技术的发展,嵌合抗原受体T细胞疗法(Chimericantigen receptor T-cell immunotherapy,CAR-T)成为目前最有发展前景的肿瘤免疫疗法之一。一般,嵌合抗原受体CAR由一个肿瘤相关抗原结合区、胞外铰链区、跨膜区域以及胞内信号转导区组成。通常,CAR包含抗体的单链片段可变(Single chain fragmentvariable,scFv)区或对肿瘤相关抗原(tumor associated antigen,TAA)具有特异性的结合结构域,其通过铰链和跨膜区与T细胞信号传导分子的胞质结构域偶联。最常见的淋巴细胞活化部分包括与T细胞效应物功能触发(例如CD3ζ)部分串联的T细胞共刺激结构域。CAR介导的过继性免疫疗法允许CAR-移植的T细胞以非HLA限制性方式直接识别靶肿瘤细胞上的TAA。
神经母细胞瘤是儿童最常见的颅外实体恶性肿瘤,其中有50%的病童被发先有肿瘤大规模的扩散与转移,常规的手术、化疗、放疗与自体干细胞移植对于这群病人的治疗效果有限,即使在控制病情达到缓解后也有80%以上的病人会于一年内复发并且死亡。治疗这些患者的一种方法是通过CAR的表达,对T细胞进行遗传修饰以靶向在肿瘤细胞上表达的抗原。CAR是经设计以人白细胞抗原(human leukocyte antigen,HLA)非依赖性方式识别细胞表面抗原的抗原受体。尝试使用表达CAR的遗传修饰细胞来治疗这些类型的患者已经取得了有前景的成功。
GD2广泛地表现在神经母细胞瘤、黑色素瘤等肿瘤当中,在正常组织中低量且局限性地表达,是一免疫治疗理想的肿瘤抗原,目前在神经母细胞瘤的免疫治疗中,发展较为成熟的有针对GD2的抗体治疗,此一方式在临床上取得初步的成功,但抗体治疗的问题在于,抗体施打后存在于外围血当中较难精准地进入肿瘤组织或肿瘤微小残留的部位,且抗体施打后无法长期存在体内,而此抗GD2抗体为人源-鼠源嵌合的抗体结构,势必会使人体对其产生抗性,增加了再治疗的困难性。
CN 106536563 A公开了包含双唾液酸神经节苷脂(GD2)结合域的嵌合抗原受体(CAR),所述GD2结合域包含a)具有互补决定区(CDR)的重链可变区;b)具有CDR的轻链可变区;及表达此类CAR的T细胞在一些癌症的治疗中的作用;该专利中的嵌合抗原受体与GD2的结合效果有待提高,其免疫效果也可以进一步提高。
因此,制备一种完全人源化的嵌合抗原受体GD2-CART细胞,除了俱有抗体治疗的优点,且因为T细胞本身的特性,可精准地进入肿瘤组织,并长期的存在于体内,必能提供复发难治的神经母细胞瘤一个更有效的治疗选择。
发明内容
针对目前CAR-T技术治疗肿瘤中靶向不十分理想,以及肿瘤微环境影响CAR-T技术治疗效果的情况,本发明提供一种基于靶向GD2的嵌合抗原受体及其应用,本发明制备的嵌合抗原受体通过将GD2-CAR-T进行基因改造,从而提高了靶点的免疫长效性与安全性,增强了CAR-T细胞的治疗效果。
为达此目的,本发明采用以下技术方案:
一方面,本发明提供一种基于靶向GD2的嵌合抗原受体,所述嵌合抗原受体包括抗原结合结构域、跨膜结构域、共刺激信号传导结构域、CD3ζ信号传导结构域和自毁结构域串联而成;
其中,所述抗原结合结构域结合肿瘤表面抗原,所述肿瘤表面抗原为GD2,所述抗原结合结构域为针对肿瘤表面抗原GD2的单链抗体,所述肿瘤表面抗原GD2的单链抗体的氨基酸序列选自:
(a)如SEQ ID NO.1-3所示的氨基酸序列;或者,
(b)如SEQ ID NO.1-3所示的氨基酸序列经过一个或多个氨基酸的取代、添加或缺失而形成的,能够特异结合在嵌合抗原受体上,具有结合GD2和诱导T细胞信号传导功能的氨基酸序列。
本发明中,通过对抗原结合结构域的单链抗体与CAR的基因结构进行特定的改造,从而使得基因修改过后的CAR-T细胞能够特异的结合在肿瘤的GD抗原上,获得相对比较适度的信号刺激,发挥有效的杀伤作用,同时缓慢释放免疫因子,降低免疫因子风暴危险,相比于其他嵌合抗原受体和其他肿瘤抗原有更好的效果与安全性。
所述针对肿瘤表面抗原GD2的单链抗体氨基酸序列(SEQ ID NO.1-3)如下:
SEQ ID NO.1所示的氨基酸序列:
HPAFLLIPQVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSSGSTSGSGKPGSSEGSTKGEIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK;
SEQ ID NO.2所示的氨基酸序列:
EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK;
SEQ ID NO.3所示的氨基酸序列:
AFLLIPEVKLVESGGGLVLPGDSLRLSCATSEFTFTDYYMTWVRQPPRKALEWLGFIRNRANGYTTEYNPSVKGRFTISRDNSQSILYLQMNTLRTEDSATYYCARVSNWAFDYWGQGTTLTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVSLGDQASISCRSSQSLLKNNGNTFLHWYLQKSGQSPKLLIYKVSNRLSGVPDRFSGSGSGTYFTLKISRVEAEDLGVYFCSQSTHIPYTFGGGTKLEIK.
本发明中,所述针对肿瘤表面抗原GD2的CAR信号结构进行了特异性改造,也能快速与不同的GD2单链抗体进行改造,使得改造后的CAR表达出来的免疫刺激力更强。
根据本发明,所述如SEQ ID NO.1-3所示的氨基酸序列经过一个或多个氨基酸的取代、添加或缺失而形成的氨基酸序列与SEQ ID NO.1-3所示的氨基酸序列具有至少90%同一性,优选为95%同一性的氨基酸序列,所述改造后的氨基酸序列仍然能够特异结合在嵌合抗原受体上,具有结合GD2和诱导T细胞信号传导功能。
所述90%同一性例如可以是90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%。
根据本发明,所述跨膜结构域为CD28跨膜结构域(CD28细胞膜外和CD28细胞膜传导结构域)和/或CD8α跨膜结构域,在一些具体实施方案中,可以通过氨基酸替换来选择或修饰跨膜结构域。
根据本发明,所述共刺激信号传导结构域为CD28信号传导结构域和4-1BB细胞内信号传导结构域的组合,所述CD28细胞外、细胞膜和细胞内传导结构域组合成CD28全信号传导结构域,所述CD28全信号传导结构域和4-1BB信号传导结构域的排列,本领域技术人员可以根据需要进行调整,CD28全信号传导结构域和4-1BB信号传导结构域不同的排列不会对所述嵌合抗原受体产生影响,本申请采用CD28-4-1BB的顺序组合所述共刺激信号传导结构域的氨基酸序列如SEQ ID NO.4所示,具体序列如下:
IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL.
其中的linker序列为多个GGGGS的重复序列。
根据本发明,所述CD28全信号传导结构域包括CD28细胞外信号、CD28细胞膜信号和CD28细胞内信号;所述CD28细胞外信号序列如SEQ ID NO.5所示,具体如下:IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP;所述CD28细胞膜信号序列如SEQ ID NO.6所示,具体如下:FWVLVVVGGVLACYSLLVTVAFIIFWV;所述CD28细胞内信号序列如SEQ ID NO.7所示,具体如下:RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSAS;
根据本发明,所述4-1BB细胞内信号序列如SEQ ID NO.8所示,具体如下:VVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL.
根据本发明,所述自毁结构域为包含胱天蛋白酶9结构域,所述胱天蛋白酶9结构域的氨基酸序列如SEQ ID NO.9所示,所述胱天蛋白酶9结构域的氨基酸序列(SEQ IDNO.9)如下:
GSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS.
根据本发明,所述自毁结构域通过2A序列与CD3ζ信号传导结构域相串联,所述2A序列会使所述自毁结构域表达的蛋白与所述嵌合抗原受体蛋白断裂开,从而使得所述嵌合抗原受体能够发挥作用,而通过注入激活剂,从而使得自毁结构域激活,从而导致嵌合抗原受体失去作用。
根据本发明,所述嵌合抗原受体还包括信号肽,所述信号肽为能够指导嵌合抗原受体跨膜转移的信号肽都是可行的,本领域技术人员可以根据需要选择本领域常规的信号肽,所述信号肽为Secretory信号肽,所述Secretory信号肽的氨基酸序列如SEQ ID NO.10-11所示,所述Secretory信号肽的氨基酸序列(SEQ ID NO.10)如下:MLLLVTSLLLCELPHPAFLLIP;或所述Secretory信号肽的氨基酸序列(SEQ ID NO.11)如下:MALPVTALLLPLALLLHAARP.
本发明的嵌合抗原受体还可以包括铰链区,所述铰链区本领域技术人员可以根据实际情况进行选择,在此不做特殊限定,铰链区的存在不会对本发明的嵌合抗原受体的性能产生影响。
本发明的嵌合抗原受体还包括启动子,所述启动子可以为EFla或任何一种高表达的启动子,本领域技术人员可以根据实际情况进行选择,在此不做特殊限定,启动子的存在不会对本发明的嵌合抗原受体的性能产生影响。
根据本发明,所述嵌合抗原受体包括信号肽、抗原结合结构域、跨膜结构域、共刺激信号传导结构域、CD3ζ信号传导结构域、2A序列和自毁结构域串联而成。
作为优选技术方案,所述嵌合抗原受体为Secretory信号肽,GD2抗原结合结构域,CD8α和/或CD28跨膜结构域,CD28全信号传导结构域、4-1BB细胞内信号传导结构域,CD3ζ信号传导结构域、2A序列和胱天蛋白酶9结构域串联而成,具体排列如下:
Secretory-GD2scFv-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9。
根据本发明,所述嵌合抗原受体Secretory-GD2scFv-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9的氨基酸序列如SEQ ID NO.12-14所示,具体如下:
SEQ ID NO.12所示的氨基酸序列:
MLLLVTSLLLCELPHPAFLLIPQVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSSGSTSGSGKPGSSEGSTKGEIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS;
SEQ ID NO.13所示的氨基酸序列:
MLLLVTSLLLCELPEVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS;
SEQ ID NO.14所示的氨基酸序列:
MLLLVTSLLLCELPAFLLIPEVKLVESGGGLVLPGDSLRLSCATSEFTFTDYYMTWVRQPPRKALEWLGFIRNRANGYTTEYNPSVKGRFTISRDNSQSILYLQMNTLRTEDSATYYCARVSNWAFDYWGQGTTLTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVSLGDQASISCRSSQSLLKNNGNTFLHWYLQKSGQSPKLLIYKVSNRLSGVPDRFSGSGSGTYFTLKISRVEAEDLGVYFCSQSTHIPYTFGGGTKLEIKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS.
第二方面,本发明提供一种病毒载体,包括第一方面所述的嵌合抗原受体。
根据本发明,所述病毒载体为慢病毒载体和/或逆转录病毒载体,优选为慢病毒载体。
第三方面,本发明提供一种T细胞,采用如第一方面所述的嵌合抗原受体通过其编码的核酸序列转染到T细胞中表达。
根据本发明,所述转染的方式为通过病毒载体和/或真核表达质粒转染到T细胞,优选为通过病毒载体转染到T细胞。
本发明中,所述T细胞具有良好的靶向杀伤作用,同时能够释放低剂量免疫因子,具备低毒性高免疫杀伤反应性质。
第四方面,本发明提供一种重组慢病毒,将包含如第二方面所述的病毒载体与包装辅助质粒pNHP和pHEF-VSVG共转染哺乳细胞得到的重组慢病毒。
根据本发明,所述哺乳细胞为293细胞、293T细胞或TE671细胞中的任意一种或至少两种的组合。
第五方面,本发明提供一种组合物,所述组合物包括如第一方面所述的嵌合抗原受体和/或如第四方面所述的重组慢病毒。
第六方面,本发明提供如第一方面所述的嵌合抗原受体、如第二方面所述的病毒载体、如第三方面所述的T细胞、如第四方面所述的重组慢病毒或如第五方面所述的组合物在制备嵌合抗原受体T细胞及其在肿瘤治疗药物中的应用;
优选地,所述肿瘤为GD2特异抗原表达的肿瘤疾病,所述GD2特异抗原表达的肿瘤疾病为神经母细胞瘤。
与现有技术相比,本发明具有如下有益效果:
(1)本发明的嵌合抗原受体通过对所述针对肿瘤表面抗原GD2的嵌合抗原受体的T细胞内共刺激信号传导结构域进行特定的基因改造,改造后的嵌合抗原受体在专一性的与GD2结合后有更好的反应效果,使得CAR-T细胞对肿瘤产生更强的免疫反应;
(2)本发明实际应用与人体后,相较于其他GD2的嵌合抗原受体T细胞,具有更高的安全性,即使发生了不良反应,由于具有诱导凋亡机制信号,也能透过诱导CAR-T细胞凋亡的药物将其撤除;
(3)本发明的嵌合抗原受体在进行CAR-T细胞回输后,可于体内长期监测到CAR-T的存在,证明其具有长效性,能使病人达到长期缓解的效用。
附图说明
图1为本发明的嵌合抗原受体的合成基因序列图谱;
图2为安全有效的慢病毒载体靶向CART应用,其中Type1为实施例1制备的嵌合抗原受体,Type2为实施例2制备的嵌合抗原受体,Type3为实施例3制备的嵌合抗原受体;
图3为三种GD2ScFv CART体外杀伤结果图,其中Type1为实施例1制备的嵌合抗原受体,Type2为实施例2制备的嵌合抗原受体,Type3为实施例3制备的嵌合抗原受体;
图4为神经母细胞瘤病人肿瘤切片免疫组化染色结果图,其中,图4(a)为肿瘤切片阴性对照,图4(b)为GD2阳性表达;
图5为GD2-CART回输神经母细胞瘤病人后毒性反应结果图;
图6为GD2-CART回输后体内CAR拷贝数侦测曲线图;
图7为神经母细胞瘤病人GD2-CART回输后以B超检测肿瘤体积变化曲线图;
图8为神经母细胞瘤病人GD2-CART回输前后腹腔肿块增强CT图片,图8(a)为回输前,图8(b)为回输后。
具体实施方式
为更进一步阐述本发明所采取的技术手段及其效果,以下结合附图并通过具体实施方式来进一步说明本发明的技术方案,但本发明并非局限在实施例范围内。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1:嵌合抗原受体的构建(I)
(1)通过全基因合成Secretory信号肽、GD2抗原结合结构域,CD28细胞外以及跨膜结构域,CD28细胞内信号传导结构域和4-1BB信号传导结构域,CD3ζ信号传导结构域、2A序列和胱天蛋白酶9结构域,如图1所示,即Secretory-GD2scFv-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9;
所述嵌合抗原受体的氨基酸序列SEQ ID NO.12如下:
MLLLVTSLLLCELPHPAFLLIPQVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSSGSTSGSGKPGSSEGSTKGEIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS。
实施例2:嵌合抗原受体的构建(II)
(1)通过全基因合成Secretory信号肽、GD2抗原结合结构域,CD28细胞外和跨膜结构域,CD28信号传导结构域和4-1BB信号传导结构域,CD3ζ信号传导结构域、2A序列和胱天蛋白酶9结构域,即Secretory-GD2scFv-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9;
所述嵌合抗原受体的氨基酸序列SEQ ID NO.13如下:
MLLLVTSLLLCELPEVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS。
实施例3:嵌合抗原受体的构建(III)
(1)通过全基因合成Secretory信号肽、GD2抗原结合结构域,CD28细胞外和跨膜结构域,CD28信号传导结构域和4-1BB信号传导结构域,CD3ζ信号传导结构域、2A序列和胱天蛋白酶9结构域,即Secretory-GD2scFv-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9;
所述嵌合抗原受体的氨基酸序列SEQ ID NO.14如下:
MLLLVTSLLLCELPAFLLIPEVKLVESGGGLVLPGDSLRLSCATSEFTFTDYYMTWVRQPPRKALEWLGFIRNRANGYTTEYNPSVKGRFTISRDNSQSILYLQMNTLRTEDSATYYCARVSNWAFDYWGQGTTLTVSSGSTSGSGKPGSSEGSTKGDVVMTQTPLSLPVSLGDQASISCRSSQSLLKNNGNTFLHWYLQKSGQSPKLLIYKVSNRLSGVPDRFSGSGSGTYFTLKISRVEAEDLGVYFCSQSTHIPYTFGGGTKLEIKAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSASGGGGSGGGGSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGGSGGGGSGGGGSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSGSGATNFSLLKQAGDVEENPGPMGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGGGGSGAMVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELARQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTSAS。
实施例4:慢病毒包装
(1)用六孔板分别培养293T细胞,1×106个细胞/孔,培养17-18小时;
(2)加入600μL/孔的新鲜的DMEM,内含10%的FBS;
(3)在无菌离心管中加入以下试剂:每孔取75μL的DMEM加入helper DNA mix(pNHP,pHEF-VSV-G,pHEF-eGFP)以及pTYF CAR DNA载体(实施例1-3),漩涡振荡;
(4)从每孔板中央吸取7μL的Superfect加至离心管中吹打5次,室温静置7-10分钟;
(5)将离心管中的DNA-Superfect混合液逐滴加入至每个培养孔中,漩涡打匀;
(6)37℃3%CO2培养箱里培养4-5小时;
(7)吸走培养基的培养液,用1.5mL AIM-V冲洗培养基,并加入1.5mL的AIM-V继续培养;
(8)将培养基放回3%CO2培养箱中培养过夜,第二天早上用荧光显微镜观察转染效率。
实施例5:慢病毒的纯化和浓缩
1)病毒纯化
通过离心(1000g,5分钟)除去细胞碎片,得到病毒上清液,用一个0.45微米的低蛋白结合过滤器将病毒上清液过滤,病毒被分装成小份,储存在-80℃;
通常情况下,在每毫升的培养基中,转染细胞可以产生106到107转导单位滴定的慢病毒载体。
2)用过滤器浓缩慢病毒载体
(1)在生物安全柜中,取过滤管,用70%酒精消毒,然后用无菌PBS清洗;
(2)每个过滤管中加入18ml的病毒上清液,然后在2500g下离心30分钟或者直到病毒体积减小20-50倍;
(3)震荡过滤管,然后在400g下,离心2分钟,收集浓缩的病毒到收集杯中,最后将所有管中的病毒集中到一个离心管中。
实施例6:CAR-T细胞的转染
将活化后的T细胞接种于培养液中并且添加10μg/mL的polybrene,培养液含有细胞培养因子IL-2、IL-7与IL-15的AIM-V,加入的浓缩CAR基因慢病毒,以100g离心力的速度,室温离心100分钟后,置于37℃培养24h,加入培养液,培养4天后,将细胞收获并计数,培养2天后输至病人。
其治疗肿瘤的效果如图2所示,能够有效使肿瘤缩小,且安全,具体将通过体外试验和体内试验分别验证。
实施例7:CAR-T细胞的体外杀伤试验
(1)将GD2阳性的肿瘤细胞株以慢病毒载体送入绿色荧光蛋白使其稳定表达;
(2)将非专一性的T细胞或不同于GD2ScFv的CAR-T细胞,与上述肿瘤置于37度5%CO2培养箱共培养24-72h;
(2)以荧光显微镜观察肿瘤细胞存活的情形,死亡的肿瘤细胞没有绿色荧光蛋白的表达,以此评估不同GD2-CAR-T细胞的体外杀伤效率,结果如图3所示;
从图3可以看出,相较于对照组T细胞,三种不同ScFv GD2-CAR-T都有明显的杀伤,又以第三种scFv的效果为最佳,因此证实此发明载体材料可以快速筛选出有效CAR结构,并进行后续临床应用。
实施例8:CAR-T细胞的治疗效果
(1)神经母细胞瘤病人的肿瘤白片由免疫组化染色确认GD2的阳性表达,结果如图4所示,从图4(a)和图4(b)可以区分出GD2表达高的肿瘤染色。
(2)采集病人白血球浓厚液,以Ficoll进行密度梯度离心法分离白血球浓厚液中的外围单个核淋巴细胞,并使用CD3磁珠筛选出T细胞并加入抗CD28的抗体进行T细胞活化,以1×106CART细胞数/公斤体重进行后续GD2-CART制备;
(3)回输前病人以小剂量化疗进行预处理,预处理方案为环磷酰胺250mg/m2使用三天,氟达拉滨25mg/m2使用三天,预处理与CART输注间隔24h,总体3天(化疗方案可以依据病人情况修改,此实施例仅仅作为一个列举);
(4)以静脉注射方式回输CART细胞;
(5)回输后由临床医生对病人进行监测与毒性反应评估,结果如图5所示;
从图5统计可看出GD2-CART的安全性,回输后有24%的病人无任何不良反应,50%的病人有一级不良反应,26%病人有二级不良反应,不良反应包括了发烧、疲倦、皮疹与低血压等等,临床上都可以有效控制;
(6)回输后定期抽取病人少量外围血,分离外围单个核淋巴细胞后抽取细胞染色体DNA(gDNA),使用专一性引物以qPCR方式定量外围血中CAR拷贝数,结果如图6所示;
从图6可看出病人回输后20天左右体内CAR值达到高峰,并可于体内维持约半年;
(7)GD2-CART回输后以影像学的方式对肿瘤大小进行评估,结果如图7和图8所示;
从图7可以看出,以B超对肿瘤进行监测,此病人在回输GD2-CART后28天腹腔与纵隔肿块相较回输前缩小约95%,并持续维持半年,此病人至今依然状况稳定;而从图8(a)-图8(b)可看出,另一病人在回输后两个月以增强CT扫描腹部肿块,肿块图8(a)原来为长1.9cm,宽4.9cm缩小至图8(b)长1.9cm,宽3.2cm。
综上所述,本发明的GD2-CART相比于其他嵌合抗原受体和其他肿瘤抗原有更好的效果,且具有安全性和长效性,对于复发难治的四期神经母细胞瘤病人确实达到很好的疗效。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (11)
1.一种基于GD2嵌合抗原受体,其特征在于,所述嵌合抗原受体为Secretory信号肽,GD2抗原结合结构域,CD8α和/或CD28跨膜结构域,CD28信号传导结构域、4-1BB信号传导结构域,CD3ζ信号传导结构域、2A序列和胱天蛋白酶9结构域串联而成;
所述嵌合抗原受体为Secretory-GD2-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9;
所述嵌合抗原受体Secretory-GD2-CD28-4-1BB-CD3ζ-2A-FBKP.Casp9的氨基酸序列如SEQ ID NO.12-14所示。
2.一种病毒载体,其特征在于,包括权利要求1所述的嵌合抗原受体。
3.根据权利要求2所述的病毒载体,其特征在于,所述病毒载体为慢病毒载体和/或逆转录病毒载体。
4.根据权利要求3所述的病毒载体,其特征在于,所述病毒载体为慢病毒载体。
5.一种T细胞,其特征在于,采用如权利要求1所述的嵌合抗原受体通过其编码的核酸序列转染到T细胞中表达。
6.根据权利要求5所述的T细胞,其特征在于,所述转染的方式为通过病毒载体和/或真核表达质粒转染到T细胞。
7.根据权利要求6所述的T细胞,其特征在于,所述转染的方式为通过病毒载体转染到T细胞。
8.一种重组慢病毒,其特征在于,将包含如权利要求6所述的病毒载体与包装辅助质粒pNHP和pHEF-VSVG共转染哺乳细胞得到的重组慢病毒。
9.根据权利要求8所述的重组慢病毒,其特征在于,所述哺乳细胞为293细胞、293T细胞或TE671细胞中的任意一种或至少两种的组合。
10.一种组合物,其特征在于,所述组合物包括如权利要求1所述的嵌合抗原受体和/或如权利要求8或9所述的重组慢病毒。
11.如权利要求1所述的嵌合抗原受体、如权利要求8或9所述的重组慢病毒或如权利要求10所述的组合物在制备嵌合抗原受体T细胞或免疫细胞及其在肿瘤治疗药物中的应用;
所述肿瘤为GD2特异抗原表达的肿瘤疾病;
所述GD2特异抗原表达的肿瘤疾病为神经母细胞瘤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810821559.9A CN108948211B (zh) | 2018-07-24 | 2018-07-24 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
JP2021503089A JP7158075B2 (ja) | 2018-07-24 | 2019-07-24 | Gd2に基づくキメラ抗原受容体及びその利用 |
US17/262,487 US20210309757A1 (en) | 2018-07-24 | 2019-07-24 | Gd2-based chimeric antigen receptor and application thereof |
PCT/CN2019/097402 WO2020020194A1 (en) | 2018-07-24 | 2019-07-24 | Gd2-based chimeric antigen receptor and application thereof |
EP19841797.4A EP3827025A4 (en) | 2018-07-24 | 2019-07-24 | GD2-BASED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810821559.9A CN108948211B (zh) | 2018-07-24 | 2018-07-24 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108948211A CN108948211A (zh) | 2018-12-07 |
CN108948211B true CN108948211B (zh) | 2021-08-20 |
Family
ID=64463690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810821559.9A Active CN108948211B (zh) | 2018-07-24 | 2018-07-24 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210309757A1 (zh) |
EP (1) | EP3827025A4 (zh) |
JP (1) | JP7158075B2 (zh) |
CN (1) | CN108948211B (zh) |
WO (1) | WO2020020194A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
CN111748043B (zh) * | 2020-07-03 | 2022-09-02 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
CN114685683A (zh) * | 2020-12-31 | 2022-07-01 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
CN114456270B (zh) * | 2022-03-02 | 2023-12-22 | 北京美康基免生物科技有限公司 | 一种gd2嵌合抗原受体及其应用 |
CN114891123B (zh) * | 2022-06-09 | 2024-02-09 | 北京美康基免生物科技有限公司 | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
CN116769723B (zh) * | 2023-08-09 | 2023-11-03 | 山东省成体细胞产业技术研究院有限公司 | 一种gd2嵌合抗原受体修饰的t细胞及其应用 |
CN117024605B (zh) * | 2023-08-15 | 2024-01-09 | 北京市眼科研究所 | 嵌合抗原受体、表达嵌合抗原受体的小胶质细胞及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726227A (zh) * | 2002-12-17 | 2006-01-25 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
CN105705165A (zh) * | 2013-03-15 | 2016-06-22 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
CN106536563A (zh) * | 2014-03-06 | 2017-03-22 | Ucl商务股份有限公司 | 嵌合抗原受体 |
CN107245107A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005206277B2 (en) * | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
FR2906808B1 (fr) * | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
US9334330B2 (en) * | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
CA2801210C (en) * | 2010-06-19 | 2020-07-21 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
ES2716298T3 (es) * | 2011-09-16 | 2019-06-11 | Baylor College Medicine | El microentorno tumoral como diana mediante el uso de células NKT manipuladas |
WO2013189516A1 (en) * | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
CN105339390A (zh) * | 2013-04-29 | 2016-02-17 | Ogd2药物 | 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略 |
EP2871190A1 (en) * | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
ES2791953T3 (es) * | 2014-06-06 | 2020-11-06 | Us Health | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
EP3842448A1 (en) * | 2015-05-15 | 2021-06-30 | City of Hope | Chimeric antigen receptor compositions |
CA2994829A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
CN106749675B (zh) * | 2016-12-27 | 2022-05-27 | 深圳市体内生物医药科技有限公司 | 一种重组慢病毒及其应用 |
CN107312097B (zh) * | 2017-07-18 | 2020-06-16 | 深圳市免疫基因治疗研究院 | 一种基于cd30的嵌合抗原受体及其应用 |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
-
2018
- 2018-07-24 CN CN201810821559.9A patent/CN108948211B/zh active Active
-
2019
- 2019-07-24 US US17/262,487 patent/US20210309757A1/en active Pending
- 2019-07-24 JP JP2021503089A patent/JP7158075B2/ja active Active
- 2019-07-24 EP EP19841797.4A patent/EP3827025A4/en active Pending
- 2019-07-24 WO PCT/CN2019/097402 patent/WO2020020194A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726227A (zh) * | 2002-12-17 | 2006-01-25 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
CN105705165A (zh) * | 2013-03-15 | 2016-06-22 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
CN106536563A (zh) * | 2014-03-06 | 2017-03-22 | Ucl商务股份有限公司 | 嵌合抗原受体 |
CN107245107A (zh) * | 2017-07-18 | 2017-10-13 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20210309757A1 (en) | 2021-10-07 |
JP7158075B2 (ja) | 2022-10-21 |
EP3827025A1 (en) | 2021-06-02 |
EP3827025A4 (en) | 2022-04-13 |
WO2020020194A1 (en) | 2020-01-30 |
JP2021531008A (ja) | 2021-11-18 |
CN108948211A (zh) | 2018-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108948211B (zh) | 一种基于靶向gd2的嵌合抗原受体及其应用 | |
JP7059405B2 (ja) | Cd19に基づくキメラ抗原受容体及びその利用 | |
US20230040878A1 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
WO2020108645A1 (en) | Cd19-and bcma-based combined car-t immunotherapy | |
CN111629734A (zh) | 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强 | |
CN109517799B (zh) | 一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用 | |
CN109880802B (zh) | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 | |
US20180142034A1 (en) | Chimeric antigen receptors and uses thereof | |
WO2020108646A1 (en) | Cd19-and psma-based combined car-t immunotherapy | |
EP3256492A1 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
JP2018510652A (ja) | Her2/erbb2キメラ抗原受容体 | |
WO2023046110A1 (zh) | 联合表达CCR2b的工程化免疫细胞及其制备和应用 | |
WO2020108642A1 (en) | Cd19-and cd30-based combined car-t immunotherapy | |
CN107400168B (zh) | 一种基于cd117的嵌合抗原受体及其应用 | |
US20160310532A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
JP7262568B2 (ja) | 免疫エフェクター細胞を使用して腫瘍を治療する方法 | |
US20210137983A1 (en) | Nk cell expansion and uses thereof | |
CA3057811A1 (en) | Chimeric antigen receptor | |
WO2023165517A1 (en) | Gd2 chimeric antigen receptor and use thereof | |
WO2023083192A1 (zh) | 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用 | |
WO2022257835A1 (en) | Cd7-based humanized chimeric antigen receptor and use thereof | |
CN117165532A (zh) | 具有增强的迁移能力的修饰的细胞 | |
WO2024037531A1 (en) | Anti-psma single-chain antibody, chimeric antigen receptor associated therewith and use thereof | |
CN115003818A (zh) | 病毒载体转导细胞的方法 | |
CN110699371A (zh) | 一种基于FcγRⅢa的嵌合基因及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |